Wolfe Research upgraded MoonLake Immunotherapeutics (MLTX) to Outperform from Peer Perform with a $61 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs
- MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating
- MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating
- Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue